TME-Responsive CAR Expression Vectors for Tumor-Specific Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-T cell therapies lack specificity in distinguishing between tumor cells and normal cells, leading to toxic immune responses and adverse effects due to the inability to constitutively express the CAR only within the tumor microenvironment.
Innovation Solution
Development of tumor environment (TME) responsive expression vectors with synthetic promoters containing multiple TME-dependent promoter response elements that induce CAR expression only in the presence of specific TME factors, ensuring minimal expression outside the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CAR expression is activated systemically to ensure potent anti-tumor activity, then tumor elimination efficiency is improved, but off-target toxicity to normal tissues increases
Solution Approach 1:
The patent implements local quality by designing CAR expression to be spatially restricted to the tumor microenvironment through TME-specific promoter elements. The promoter contains response elements that are activated only by factors present in the TME (such as hypoxia, inflammatory cytokines, or specific enzymes), ensuring that CAR is expressed locally at the tumor site while remaining inactive in normal healthy tissues. This resolves the contradiction by concentrating anti-tumor activity where needed while sparing normal tissues from toxicity.
Solution Approach 2:
The patent applies dynamics by creating a conditional CAR expression system that can adapt its activity level based on the local environment. The TME-responsive promoter allows CAR expression to dynamically increase in response to TME-specific signals (such as hypoxia-inducible factors or inflammation-mediated transcription factors) and decrease or remain inactive in normal tissues. This dynamic regulation enables the system to maximize tumor elimination while minimizing off-target effects.
2Reliability
If CAR expression is restricted to tumor microenvironment to reduce off-target effects, then safety is improved, but tumor elimination efficiency may be reduced
Solution Approach 1:
The patent utilizes parameter changes by designing the TME-responsive promoter to respond to multiple TME-specific parameters simultaneously (such as hypoxia levels, pH, inflammatory cytokine concentrations, or enzymatic activity). By combining multiple response elements in the promoter, the system ensures that CAR expression is activated only when the characteristic parameter profile of the TME is detected, providing both high safety through strict localization and high efficiency through robust activation in the target environment.
3Ease of manufacture
If constitutive CAR expression is used to simplify the treatment design, then ease of manufacture is improved, but specificity between tumor and normal cells deteriorates
Solution Approach 1:
The patent applies segmentation by dividing the promoter region into distinct functional modules: a basal promoter core and multiple TME-responsive element modules. Each response element module can independently detect specific TME conditions. This modular segmentation allows for relatively straightforward construction of the CAR construct while achieving high specificity, as the segmented promoter only activates when the complete set of TME conditions is met, preventing activation in normal tissues.
Data Source
AI summary
A Tumor Micro-Environment (TME) responsive expression vector including a nucleic acid sequence of a synthetic promoter, comprising two or more promoter-response-elements inducing expression of an immune-effector gene.